Raynovent Announces Ethical Approval for Phase 1b /2a Clinical Trial of ZSP1601, a Category 1 Drug in Development for The Treatment of NASH.

Time:2019.06.25Views:66Author:众生睿创

Previous:Raynovent Announces Receiving of Certificate of Invention Patent in United States in Japan

Next:Raynovent Announces Ethical Approval for Phase 2 Clinical Trial of Category 1 Drug ZSP1273.